ArticleAntimicrobial agents and chemotherapy2020
Nonstationary Pharmacokinetics of Caspofungin in ICU Patients.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Population pharmacokinetics of caspofungin in critically ill Chinese children: a prospective observational study.Antimicrobial agents and chemotherapy · 2026Observational
- Development and Quality Control of a Population Pharmacokinetic Model Library for Caspofungin.Pharmaceutics · 2024Article
- Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients.Antibiotics (Basel, Switzerland) · 2023Article
- Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19.Clinical pharmacokinetics · 2023Article
- A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: The SAFE-ICU study.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2023Article
- Population Pharmacokinetics of Caspofungin and Dose Simulations in Heart Transplant Recipients.Antimicrobial agents and chemotherapy · 2022Article
- Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?Antibiotics (Basel, Switzerland) · 2022Review
- Pharmacokinetics/Pharmacodynamics of Caspofungin in Plasma and Peritoneal Fluid of Liver Transplant Recipients.Antimicrobial agents and chemotherapy · 2022Article
- The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations.Frontiers in pharmacology · 2022Article
- New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis.Gels (Basel, Switzerland) · 2021Article
- Effects ofFrontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard dosing of caspofungin in critically ill patients has been reported to result in lower drug exposure, which can lead to subtherapeutic 24-h area under the curve to MIC (AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.